Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The ENERGY 2 Study is an open-label Phase 3 trial called “The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency.” It aims to test if INZ-701 can safely improve outcomes in infants with this rare, severe genetic disease.
The study tests INZ-701, a lab-made fusion protein designed to replace missing ENPP1 activity in the body. It is given as a weekly under-the-skin injection and is intended to prevent problems like weak bones and blood vessel calcification seen in ENPP1 deficiency.
The trial is interventional with one single treatment group and no placebo arm, which is common in ultra-rare pediatric diseases. It is open-label, so doctors and families know the child is getting INZ-701, and the main goal is to see if the drug can treat the disease while remaining safe.
The study began enrolling on March 11, 2026, marking the formal start of clinical testing in this infant group. The latest protocol update was submitted on March 16, 2026, signaling that the design and operational details are current and that the trial is actively recruiting.
For investors, the update underscores BioMarin’s role as a collaborator alongside Inozyme Pharma and its strategic interest in rare bone and mineral disorders. Positive signals from this trial could support sentiment for both companies by reinforcing their positions in high-value rare disease markets where competition is limited but pricing power is strong.
While INZ-701 is led by Inozyme, BioMarin’s involvement aligns with its broader rare-disease portfolio and may hint at future partnering, co-commercialization, or pipeline expansion opportunities. The study is currently ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about BMRN’s potential, visit the Biomarin Pharmaceutical Inc. drug pipeline page.